Secretin: The First Hormone — Pancreatic Research, Neuroendocrine Signaling, and the Brain-Gut Water Axis (2026)

# Secretin: The First Hormone — Pancreatic Research, Neuroendocrine Signaling, and the Brain-Gut Water Axis (2026)

Secretin holds a unique place in the history of biology. When William Maddock Bayliss and Ernest Henry Starling isolated it from the duodenal mucosa in 1902, they did more than identify a new molecule — they invented the concept of a hormone. Their finding that a chemical messenger produced by the gut could travel through the blood to stimulate the pancreas established the foundational paradigm of endocrinology. More than a century later, secretin continues to generate research interest, not just as a classical GI regulator but as a neuropeptide with roles in brain water homeostasis, social behavior, synaptic plasticity, and bone metabolism.

Secretin is a 27-amino-acid peptide of the glucagon/secretin superfamily (Class B GPCR ligand family), encoded by the SCT gene and primarily produced by S cells of the duodenum. Its cognate receptor, the secretin receptor (SCTR), was the first Class B GPCR to be molecularly cloned, in 1991, making this peptide–receptor pair foundational for the structural pharmacology of this entire receptor class — which includes receptors for GLP-1, GIP, glucagon, PTH, PACAP, VIP, and CRH.

> Research Use Only: All secretin research compounds are sold strictly for laboratory investigation. This profile is intended for researchers and does not constitute medical advice, clinical guidance, or endorsement for human or animal use.

---

Historical Context: The Birth of Endocrinology

In 1902, Bayliss and Starling demonstrated that acid applied to the duodenal mucosa stimulated pancreatic secretion even after the nerves to the pancreas had been cut — proving that a chemical signal, not a nerve signal, drove the response. They named this signal "secretin" and the concept they formalized became the definition of a hormone: a chemical messenger released into the bloodstream from one tissue to act on a distant target organ.

This discovery launched endocrinology as a discipline. The secretin receptor (SCTR), cloned in 1991, was the founding member of the Class B (family B) G protein-coupled receptor superfamily, now recognized as a structurally distinct receptor family encompassing some of the most pharmacologically important targets in metabolic and neuroendocrine research — including the GLP-1 receptor, glucagon receptor, GIP receptor, PTH receptor, and PACAP/VIP receptors.

---

Structure and the Secretin/Glucagon Peptide Superfamily

Human secretin is a linear 27-amino-acid peptide (HSDGTFTSELSRLREGARLQRLLQGLV). Its N-terminal histidine is critical for receptor activation — a feature shared across the glucagon/secretin peptide family. Secretin shares significant sequence homology with:

• •Glucagon (~40% identity) — GI and hepatic metabolism regulator
• •GLP-1 and GLP-2 — incretin and intestinal growth peptides
• •GIP — incretin and dual receptor agonist component
• •VIP — pleiotropic neuropeptide (see VIP Research Profile)
• •PACAP — neuroprotective hypothalamic peptide (see PACAP Research Profile)
• •Glucagon (GCG gene family) — see Glucagon Research Profile

This structural family unity means that secretin research is inherently comparative — understanding SCTR pharmacology provides context for the entire Class B receptor landscape, including the GLP-1 receptor that drives modern metabolic research.

Biosynthesis and Release

Secretin is synthesized as a 121-amino-acid preprosecretin precursor and processed to the mature 27-aa form by prohormone convertases in S cells. S cells are concentrated in the duodenum and proximal jejunum, with decreasing density distally.

Key stimuli for secretin release include:

• •Luminal acid — the primary physiological trigger; gastric acid entering the duodenum is the main stimulus
• •Fatty acids — medium- and long-chain fatty acids stimulate S cell secretion
• •Bile salts — contribute to S cell activation in some experimental conditions
• •Hyperosmolarity — osmotic stimuli activate S cells, relevant to water homeostasis research

After release, secretin circulates with a short plasma half-life of approximately 2.5 minutes, acting on the pancreas, liver, stomach, and intestine via SCTR.

---

Secretin Receptor: Class B GPCR Biology

The secretin receptor (SCTR) is a 449-amino-acid Class B GPCR with a large N-terminal extracellular domain essential for high-affinity peptide binding — a defining structural feature of all class B GPCRs. Ligand binding occurs through a two-step mechanism:

1. Initial capture: The C-terminal region of secretin binds the large N-terminal ECD of SCTR, aligning the peptide

2. Activation: The N-terminal histidine of secretin inserts into the transmembrane bundle, engaging the receptor core and activating Gαs

Signaling downstream of SCTR activation includes:

• •cAMP/PKA — the dominant pathway; drives fluid and bicarbonate secretion in pancreatic ductal cells
• •PI3K/Akt — implicated in SCTR-mediated cell survival and neuroprotection
• •PKC/Ca²⁺ — activated via Gαq coupling in certain cell types
• •MAPK/ERK — relevant to secretin's mitogenic and neurotrophic effects

Ligand binding and the activation mechanism of SCTR have been characterized in detail as a model for the entire Class B GPCR family (PMC 3415634). SCTR expression is found in pancreatic ductal cells, hepatocytes, parietal cells, duodenal epithelium, choroid plexus, and multiple CNS regions.

---

Pancreatic Research: Bicarbonate Secretion and Ductal Function

The classical and most extensively studied action of secretin is stimulation of bicarbonate-rich fluid secretion from pancreatic ductal cells — the "alkaline tide" that neutralizes gastric acid entering the duodenum and creates the optimal pH for pancreatic enzyme activity.

Mechanism of Pancreatic Bicarbonate Secretion

SCTR activation in pancreatic duct cells drives:

1. cAMP/PKA-dependent CFTR activation — the cystic fibrosis transmembrane conductance regulator is the primary Cl⁻/HCO₃⁻ exchanger in ductal cells; PKA phosphorylation activates CFTR, enabling HCO₃⁻ secretion

2. Aquaporin-1 (AQP1) regulation — secretin promotes water flux through AQP1 on ductal cells, producing high-volume bicarbonate-rich pancreatic juice

3. Chloride channel activation — Cl⁻ secretion through CFTR drives paracellular water movement

The secretin-CFTR axis has important implications for cystic fibrosis research: CF patients with CFTR mutations have severely impaired secretin-stimulated bicarbonate secretion, contributing to pancreatic insufficiency. Secretin stimulation testing remains a research tool for assessing pancreatic exocrine function.

CCK Synergy in Pancreatic Research

Secretin does not act in isolation — it synergizes potently with cholecystokinin (CCK) to maximize enzyme secretion from pancreatic acinar cells. CCK drives enzyme synthesis and secretion, while secretin provides the fluid and bicarbonate vehicle for enzyme delivery. This CCK-secretin synergy is a fundamental principle of pancreatic physiology research. For the CCK research profile, see the CCK Research Profile.

Hepatobiliary Research

Beyond the pancreas, secretin acts on bile duct epithelial cells (cholangiocytes) to stimulate bicarbonate-rich bile secretion — the "biliary bicarbonate umbrella" that protects bile duct epithelium from bile acid toxicity. Disruption of this protective mechanism has been implicated in cholestatic liver disease research, making SCTR in cholangiocytes a relevant research target for hepatobiliary biology.

---

Neuroendocrine Research: Secretin as a Neuropeptide

For decades, secretin was considered purely a GI peptide. The discovery of secretin and SCTR expression throughout the CNS fundamentally changed that view, establishing secretin as a genuine neuropeptide with roles in brain development, synaptic plasticity, and complex behaviors.

CNS Distribution of Secretin and SCTR

Secretin and its receptor are expressed in multiple brain regions:

• •Cerebellum — Purkinje cells and granule cells; among the highest CNS expression sites
• •Hippocampus — CA1, CA3 pyramidal neurons; relevant to memory and plasticity research
• •Hypothalamus — paraventricular nucleus (PVN), arcuate nucleus; energy homeostasis and neuroendocrine regulation
• •Amygdala — central amygdala; relevant to social behavior and anxiety research
• •Cerebral cortex — widespread cortical expression
• •Brainstem — nucleus tractus solitarius; gut-brain communication hub
• •Subfornical organ (SFO) — circumventricular organ critical for thirst regulation

A comprehensive review of the central mechanisms of secretin in regulating multiple behaviors documented this distributed CNS expression (PubMed 24904528).

Cerebellar Research

The cerebellum represents the highest CNS expression site for both secretin and SCTR. Here, secretin functions as a retrograde messenger — released from Purkinje cells, it signals back to granule cell axon terminals. Key cerebellar findings include:

• •Secretin modulates inhibitory post-synaptic currents (IPSCs) in Purkinje cells via pre-synaptic SCTR
• •Secretin-SCTR signaling in the cerebellum influences motor learning and coordination
• •SCTR knockout mice show altered cerebellar-dependent motor behaviors

Synaptic Plasticity Research

Secretin receptor-deficient mice exhibit impaired hippocampal synaptic plasticity, with reduced long-term potentiation (LTP) at Schaffer collateral–CA1 synapses and slightly fewer dendritic spines in CA1 pyramidal neurons. These animals also display abnormal social and cognitive behaviors (PubMed 17008357). The involvement of secretin in controlling cell survival and synaptic plasticity in the CNS has been reviewed in detail (PMC 7218122).

---

Water Homeostasis and Thirst Research

One of the most striking recent discoveries in secretin biology is its role as a gut-derived signal that activates the brain's thirst circuit — directly linking GI osmosensing to central water intake control.

Secretin as a Neurohypophysial Factor

Early research established that secretin is present in the pituitary gland and can modulate vasopressin (AVP) release, implicating it in water balance regulation (PubMed 19805236). Secretin stimulates AVP release from the posterior pituitary, providing a mechanism by which gut-derived secretin can communicate systemic osmotic status to the hypothalamo-pituitary axis. This broader water homeostasis role was reviewed in PubMed 20944548.

Subfornical Organ (SFO) Thirst Circuit Research

A landmark 2022 study published in Current Biology identified a specific neural mechanism by which secretin drives thirst:

• •SCTR is expressed on nitric oxide synthase-positive (nNOS⁺) excitatory neurons in the subfornical organ (SFO) — a circumventricular organ that monitors blood osmolality and drives water intake
• •Selective deletion of SCTR specifically in SFO neurons significantly reduced water intake in dehydrated mice, while salt intake was unaffected
• •Secretin activates SFO nNOS⁺ neurons through SCTR-mediated inward currents
• •The SFO → median preoptic nucleus (MnPO) projection, when SCTR is ablated, fails to properly activate the drinking response
• •This finding provides the first direct molecular mechanism linking gut-secreted secretin to the brain's thirst-driving neural circuit (PubMed 36220076)

This discovery positions secretin as a key gut-brain axis signal for coordinating GI osmosensing with behavioral water intake — a finding with broad implications for body fluid homeostasis research.

Choroid Plexus and CSF Water Dynamics

Secretin acts on choroid plexus epithelial cells to modulate cerebrospinal fluid (CSF) production. SCTR expression in the choroid plexus and secretin's ability to alter aquaporin expression in this tissue position it as a regulator of brain water dynamics distinct from its peripheral actions. Research into this axis has implications for understanding CSF volume regulation and hydrocephalus research models.

---

Social Behavior, Autism Spectrum Research, and SCTR

An unusual chapter in secretin research concerns its proposed connection to autism spectrum disorder (ASD). In 1998, an anecdotal report described language and social improvements in three autistic children following IV secretin administration, triggering significant research interest.

SCTR Knockout Mouse Phenotype

The social behavior phenotype of SCTR-deficient mice provides mechanistic context for the autism research connection:

• •Reduced social interaction and impaired social memory
• •Abnormal cognitive flexibility
• •Disrupted hippocampal LTP — consistent with cognitive phenotypes
• •Normal anxiety-like behavior and locomotion, suggesting specificity of the social/cognitive phenotype

This phenotype, combined with the expression of SCTR in brain regions implicated in social behavior (hippocampus, amygdala), motivated research into whether secretin signaling modulates human social cognition (PubMed 15176437).

Controlled Research Findings

Subsequent controlled research largely failed to confirm the initial anecdotal reports of secretin benefit in autism. A systematic review of secretin for autism spectrum disorders concluded that available evidence does not support secretin as an effective treatment in controlled conditions (PMC 3387870). An earlier review similarly found no reliable evidence for efficacy (PubMed 11847953).

However, the SCTR knockout mouse phenotype and the mechanistic data on secretin in hippocampal plasticity and social brain circuits suggest that the secretin system warrants continued investigation as a component of social neurobiology research — even if direct secretin supplementation does not produce consistent behavioral effects.

---

Bone and Energy Metabolism Research

A 2024 study published in Nature Communications identified an unexpected role for secretin in energy metabolism and bone homeostasis mediated by secretin signaling in the ventromedial hypothalamus (VMH). Key findings:

• •Secretin-dependent signals in the VMH regulate energy metabolism and bone mineral density in mice
• •This hypothalamic axis reveals a gut-brain-bone signaling loop connecting pancreatic secretion physiology to skeletal biology
• •These findings expand the research mandate for secretin beyond the GI tract into neuroendocrine-skeletal integration

For context, this connects to ongoing research on gut peptides in bone metabolism, a field that has accelerated alongside GLP-1 agonist research. See also the Glucagon Research Profile for related metabolic bone connections.

---

Secretin Research Tools and Assays

---

Key Research Findings Summary

---

Research Limitations and Outstanding Questions

1. Short plasma half-life (~2.5 min): Rapid clearance limits in vivo research with exogenous secretin; stable analogs and prodrug approaches are areas of active development

2. Gut vs. brain secretin: The relative contribution of peripherally-produced vs. centrally-produced secretin to CNS effects is not fully resolved; the degree to which circulating gut secretin penetrates the blood-brain barrier is debated

3. Autism mechanism: While SCTR KO mice show social phenotypes and controlled human research has not confirmed behavioral benefit of secretin supplementation, the mechanistic disconnect remains unexplained

4. Class B GPCR structural pharmacology: Secretin research benefits from the structural pharmacology of the Class B GPCR family but secretin-specific structural data lags behind GLP-1R and GCGR, which have been more extensively studied by cryo-EM

5. Biased agonism: Whether functionally biased secretin analogs can selectively drive pancreatic vs. CNS effects through SCTR remains unexplored

---

Summary

Secretin is the molecule that invented the concept of a hormone. First isolated in 1902, this 27-amino-acid Class B GPCR ligand remains biologically fascinating more than a century after its discovery. In the GI system, secretin drives pancreatic bicarbonate secretion through CFTR-dependent mechanisms, synergizes with CCK for maximal pancreatic output, and protects biliary epithelium. Its receptor was the founding member of the Class B GPCR family, positioning secretin research at the heart of structural pharmacology for an entire receptor superfamily that includes the GLP-1 receptor.

Beyond the GI tract, secretin operates as a genuine neuropeptide — regulating hippocampal synaptic plasticity, cerebellar Purkinje cell function, and, in a 2022 breakthrough finding, directly activating the brain's thirst circuit through SCTR on subfornical organ neurons. The emerging connections between secretin signaling and bone metabolism, energy homeostasis, and social behavior ensure that this ancient hormone will continue generating new research questions for decades to come.

---

All secretin research compounds described herein are intended exclusively for laboratory investigation under Research Use Only (RUO) conditions. This content does not constitute medical advice, clinical guidance, or endorsement for human or animal use.